HOME
>
基礎医学
>
病理学
> 癌診療指針のための病理診断プラクティス　リンパ球増殖疾患

癌診療指針のための病理診断プラクティス　リンパ球増殖疾患

出版社：	中山書店
著者：	青笹克之／総編集
発行日：	2010-11-29
分野：	基礎医学 > 病理学
ISBN：	9784521733326
シリーズ：	癌診療指針のための病理診断プラクティス
電子書籍版：	2010-11-29 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

19,800 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

商品紹介

腫瘍の診断において中心的役割をつとめる病理診断は，画像医学の進歩とともにその重要性を増している。本書では，病理医，臨床医が互いに理解を深められるよう，病理診断の基本が解説してある．また，鑑別診断の章では疾患別にフローチャートを用意し，鑑別すべき病理像も豊富に掲載し，病理医だけでなく，臨床の医師にも活用しやすい，実用のための書籍となっている。

目次

癌診療指針のための病理診断プラクティス　リンパ球増殖疾患

―目次―

1章　病理診断の流れとポイント
2章　診断のための基本知識
3章　リンパ球増殖疾患の鑑別診断
4章　病理検体の取扱
5章　症例の実際

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

2章診断のための基本知識

P.10 掲載の参考文献

1) 名倉宏, 長村義之, 堤寛編. 渡辺・中根酵素抗体法. 改訂4版. 学際企画 ; 2002.

P.19 掲載の参考文献

1) Shapiro HM. Practical Flow Cytometry. Wiley-Liss ; 2003.

2) Watson JV. Flow Cytometry Data Analysis : Basic Concepts and Statistics. Cambridge University Press ; 2005.

3) Nguyen DT. Flow Cytometry in Hematopathology : A Visual Approach to Data Analysis and Interpretation (Current Clinical Pathology). Humana Press ; 2007.

4) 室井一男ほか編. フローサイトメトリーを用いた造血器腫瘍の診断. 医薬ジャーナル社 ; 2006.

P.25 掲載の参考文献

1) Rezuke WN, et al. Molecular diagnosis of B- and T-cell lymphomas : fundamental principles and clinical applications. Clin Chem. 1997 ; 43 (10) : 1814-23.

2) Beishuizen A, et al. Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis : recommendations for optimal results. Leukemia. 1993 ; 7 (12) : 2045-53.

3) van Dongen JJ, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations : report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003 ; 17 (12) : 2257-317.

P.32 掲載の参考文献

1) Tatsumi M, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma : initial experience. Radiology. 2005 ; 237 : 1038-45.

2) Juweid ME, et al. Use of positron emission tomography for response assessment of lymphoma : consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 ; 2 : 571-8.

3) Isohashi K, Tatsumi M, Higuchi I, et al. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up : staging and restaging, and evaluation of treatment response and recurrence. Ann Nucl Med. 2008 ; 22 : 795-802.

4) Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET : a comparison with CT and endoscopic findings. Ann Nucl Med. 2008 ; 22 : 261-7.

P.40 掲載の参考文献

1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993 ; 329 : 987-94.

2) Pfreundschuh M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 ; 7 : 379-91.

3) Miller TP, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 ; 339 : 21-6.

4) Sehn LH, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 ; 109 : 1857-61.

5) Solal-Celigny P, et al. Follicular lymphoma international prognostic index. Blood. 2004 ; 104 : 1258-65.

6) Tsukasaki K, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 ; 25 : 5458-64.

7) Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 ; 339 : 1506-14.

8) 日本造血細胞移植学会. 造血幹細胞移植の適応ガイドライン・悪性リンパ腫. 2002.

9) Okamura J, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005 ; 105 : 4143-5.

3章リンパ球増殖疾患の鑑別診断

P.54 掲載の参考文献

1) Guerrero-Medrano J, et al. Signet-ring sinus histiocytosis. A reactive disorder that mimics metastatic adenocarcinoma. Cancer. 1997 ; 80 : 227-85.

2) Rosai J, et al. Sinus histiocytosis with massive lymphadenopathy ; a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer. 1972 ; 30 : 1174-88.

3) Foucar E, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) : Review of entity. Semin Diagn Pathol. 1990 ; 7 : 19-73.

P.134 掲載の参考文献

1) Muller-Hermelink HK, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In : Swerdlow SH, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva : WHO press ; 2008, p.180-2

2) Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995 ; 333 : 1052-7.

3) Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guideline. Blood. 2008 ; 111 : 5446-56.

4) Chiorazzi N, et al. Chronic Lymphocytic Leukemia. N Engl J Med. 2005 ; 352 : 804-15.

5) Rai KR, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 ; 46 : 219-34.

6) Binet JL, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 ; 48 : 198-206.

7) Binet JL, et al. Perspective on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 ; 107 : 859-61.

8) Hamblin TJ, et al. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 ; 94 : 1848-54.

9) Wiestner A, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with un mutated immunoglobulin genes, inferior clinical outcome, and distinct gne expression profile. Blood. 2003 ; 101 : 4944-51.

10) Gjia P, et al. The pattern of CD38 expression defines a distinct seubset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003 ; 101 : 1262-9.

11) Dohner H, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 ; 343 : 1910-6.

12) Rossi D, Gaidano G. Richter syndrome : molecular insights and clinical perspectives Hamtol Oncol. 2009 ; 27 : 1-10.

P.143 掲載の参考文献

1) Swerdlow, SH, et al. Lymphoplasmacytic lymphoma. In : Swerdlow SH, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva : WHO press ; 2008, p. 194-5.

2) Lin P, et al. Diffuse large B-cell lymphoma occuurring in patients with lymphoplasmacytic/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol. 2003 ; 120 : 246-53.

3) Treon SP, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006 ; 17 : 488-94.

4) Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood. 2007 ; 109 : 5096-103.

5) Li n P, et al. Lymphoid neoplasms associated with IgM paraprotein : A study of 382 patients. Am J Clin Pathol. 2005 ; 123 : 200-5.

6) Dimopoulos MA, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 ; 27 : 120-6.

7) Ocio EM, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 136 ; 80-6.

P.172 掲載の参考文献

1) Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In : Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of haematopoietic and lymphoid tissues. Geneva : WHO Press ; 2008. p.214-7.

2) Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 ; 342 : 575.

3) Inagaki H. Mucosa-associated lymphoid tissue lymphoma : molecular pathogenesis and clinicopathological significance. Pathol Int. 2007 ; 57 : 474-84.

4) Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009 ; 459 : 712-6.

5) Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior : analysis of 108 patients. J Clin Oncol. 1997 ; 15 : 1624-30.

6) Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000 ; 95 : 802-6.

7) Wohrer S, Streubel B, Bartsch R, et al. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res. 2004 ; 10 : 7179-81.

8) Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stromach with radiation alone. J Clin Oncol. 1998 ; 16 : 1916-21.

9) Campo E, Pileri SA, Jaffe ES, et al. Nodal marginal zone lymphoma. In : Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of haematopoietic and lymphoid tissues. Geneva ; WHO Press ; 2008 p. 218-9

10) Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol. 2008 ; 19 : iv70-3.

11) Munga-Penas EM, Roser K, Cpie-Bergman C, et al. Translocation t (11 ; 18) (q21 ; q21) and t (14 ; 18) (q32 ; q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia. 2003 ; 17 : 2225-9.

12) Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004 ; 100 : 107-15.

13) Salama ME, Lossos IS, Warnke RA, et al. Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma : A Study of 51 cases. Am J Clin Pathol. 2009 ; 132 : 39-49.

14) Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma : clinical features and prognostic assessment of a rare disease. Be J Haematol. 2007 ; 136301-4.

15) Bertoni F, Zucca E. State-of-art therapeutics : marginal-zone lymphoma. J Clin Oncol. 2005 ; 23 : 6415-20.

16) Isaacson PG, Thieblemont D, Piris MA, et al. Splenic marginal zone lymphoma. In : Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of haematopoietic and lymphoid tissues. Geneva : WHO Press ; 2008, p.185-7.

17) Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008 ; 22 : 487-95.

18) Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol. 2008 ; 19 : iv70-3.

19) Melo JV, Hedge U, Parreira A, et al. Splenic B cell lymphoma with circulating villous lymphocytes : differential diagnosis of B cell leukemias with large spleens. J Clin Pathol. 1987 ; 40 : 642-51.

20) Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV (H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002 ; 99 : 1299-304.

21) Watkins AJ, Huang Y, Ye H, et al. Splenic marginal zone lymphoma : characterization of 7q deletion and its value in diagnosis. J Pathol. 2010 ; 220 : 461-74.

22) Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virusassociated marginal zone lymphomas. Leukemia. 2004 ; 18 : 1711-6.

23) Bertoni F, Zucca E. State-of-art therapeutics : marginal-zone lymphoma. J Clin Oncol. 2005 ; 23 : 6415-20.

24) Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma : splenectomy versus rituximab. Semin Hematol. 2010 ; 47 : 143-7.

25) Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma : clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002 ; 100 : 1648-54.

26) Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma : a prognostic model for clilncial use. Blood. 2006 ; 107 : 4643-9.

P.197 掲載の参考文献

1) Said J, Cesarman E. Primary effusion lymphoma. In : Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. 4th ed. Lyon : International Agency for Research on Cancer (IARC) ; 2008. p. 260-1.

2) Isaacson PG, et al. Large B-cell lymphoma arising in HHV-8-associated multicentric Castleman disease. In : Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. 4th ed. Lyon : International Agency for Research on Cancer (IARC) ; 2008. p.258-9.

P.227 掲載の参考文献

1) Swerdlow SH, Campo E, Harris NL, eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press ; 2008.

2) Attygalle A, Al-jehan R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002 ; 99 : 627-33.

3) Smith JL, Hodges E, Quin CT, et al. Frequent T and B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy. Am J Pathol. 2000 ; 156 : 661-9.

4) Mourad N, Mounier N, Briere J, et al. Clinical, biological, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated with the Groupe d'Etude des lymphomes de l'Adulte (GELA) trials. Blood. 2008 ; 111 : 4463-70.

5) Rodriguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T cell lymphoma with follicular T-cell markers. AM J Surg Pathol. 2008 ; 32 : 1780-99.

6) Rodriguez-Justo M, Attygalle AD, Munson P, et al. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers. A neoplasia with origin in the outer zone of the germinal centre? Mod Pathol. 2009 ; 22 : 753-61.

7) Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood. 1994 ; 84 : 2640-8.

8) Attygalle AD, Kyriakou C, Dupuis J, et al. Histological evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies. Am J Surg Pathol. 2007 ; 31 : 1077-88.

9) Rodriguez J, Conde E, Guitierrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Eur J Haematol. 2007 ; 78 : 290-6.

P.236 掲載の参考文献

1) Stein H, Foss H-D, Durkop H, et al. CD30+ anaplastic large cell lymphoma : a review of its histopathologic, genetic, and clinical features. Blood. 2000 ; 96 : 3661-95.

2) Swerdlow SH, Campo E, Harris NL, eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press ; 2008.

3) Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPN-ALK-positive anaplastic large cell lymphoma. Blood. 2007 ; 110 : 670-7.

4) Nguyen JT, Condron MR, Nguyen ND, et al. Anaplastic large cell lymphoma in leukemic phase. Pathol Int. 2009 ; 59 : 345-53.

5) Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004 ; 104 : 3358-60.

6) Le Deley M-C, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma : results of a large European intergroup study. Blood. 2008 ; 111 : 1560-6.

7) Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified. Blood. 2008 ; 111 : 5496-504.

8) Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma. Am J Surg Pathol. 2006 ; 30 : 223-9.

P.263 掲載の参考文献

1) Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. 1991 ; 325 : 1078-108.

2) Gonzalez CL, Medeiros LJ, Braziiel RM, et al. T-cell lymphoma involving subcutaneous tissue : a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991 ; 15 : 17-27.

3) Kumar S, Krenacs L, Elenitoba-Johnson K, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T-lymphocytes. Hum Pathol. 1998 ; 29 : 397-403.

4) Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma : clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998 ; 22 : 881-93.

5) Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathological differences between 22 cases of CD56-negative and CD56-positive subcutaneous pannuculitis-like lymphoma in Japan. Human Pathol. 2004 ; 35 : 231-9.

6) Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003 ; 101 : 3407-12.

7) Willemze R, Jansen P, Cerroni L, et al. Subcutaneous panniculitis-like T cell lymphoma : definition, classification, and prognostic factors : an EORTC cutaneous lymphoma group study of 83 cases. Blood. 2008 ; 111 : 838-45.

8) Pincus LB, LeBoit PE, McCalmont TH, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping features of lupus erythematosus. Am J Dermatopathol. 2009 ; 31 : 520-6.

P.295 掲載の参考文献

1) Weitzman S, Egeler M, editors. Histiocytic disorders of children and adults. Cambridge : Cambridge University Press ; 2005.

2) Jaffe R, et al. Tumours derived from Langerhans cells. In : Swerdlow SH, et al, editors. WHO classification of tumours, tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon : IARC ; 2008. p. 358-60.

3) Bank MI, et al. LCH. APMIS. 2003 ; 111 : 300-8.

4) Howarth DM, et al. LCH. Cancer. 1999 ; 85 : 2278-90.

5) 厚生労働省難治性疾患克服研究事業「乳児LCHの病態解明と診療研究」班報告 ver.2010/01

6) Morimoto A, et al. Improved outcome in the treatment of pediatric multifocal LCH : Results from the Japan LCH Study Group-96 protocol study. Cancer. 2006 ; 107 : 613-9.

7) Gadner H, et al. Improved outcome in multisystem LCH is associated with therapy intensification. Blood. 2008 ; 111 : 2556-62.

8) Minkov M, et al. Reactivations in multisystem LCH : data of the international LCH registry. J Pediatr. 2008 ; 153 : 700-5.

9) Bernstrand C, et al. Pulmonary abnormalities at longterm follow-up of patients with LCH. Med Pediatr Oncol. 2001 ; 36 : 459-68.

10) Morimoto A, et al. Nationwide survey of single-system single site LCH in Japan. Pediatr Blood Cancer. 2010 ; 54 : 98-102.

11) da Costa CE, et al. No genomic aberrations in LCH as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009 ; 48 : 239-49.

12) Pileri SA, et al. Tumors of histiocytes and accessory dendritic cells. Histopathology. 2002 ; 41 : 1-29.

13) Badalian-Very G, et al. Recurrent BRAF mutation in Langerhans cell histiocytosis. Blood. 2010 : prepublished on line June 2.

書評

書評を投稿する

最近チェックした商品履歴

Loading...